daratumumab

[키워드] anti-cancer treatment anti-CD38 anti-SARS-CoV-2 anti-SARS-CoV-2 IgG approved assumed basal BNT162b2 BNT162b2 mRNA BNT162b2 mRNA vaccine BNT162b2 vaccine booster Cancer chemiluminescent immunoassay chronic myeloid leukemias Cohort cohorts Committee Concentration Concordance Contagion Control Cutoff daratumumab demonstrated disease dose Endpoint evaluated Evidence family family members FDA first dose Gender geometric mean Geometric mean concentrations geometric mean ratio geometric mean ratios GMC GMCs hematological Hematological malignancy IgG IgG test immunogenic immunogenicity increasing age IRCCS Lazio less leukemia likelihood Linear model logarithm maintain Mann–Whitney test Mask Masks mRNA vaccine Multiple myeloma myeloproliferative malignancies myeloproliferative malignancy myeloproliferative neoplasms neutralization test Neutralizing of BNT162b2 Patient patients plaque Plaque reduction neutralization test positive Preliminary data primary endpoint Protective Quantitative reduce Responder responders response response rates Result risk robust S1/S2 Safety SARS-CoV-2 Serologically Seroprotection rate significantly social distancing Swab swabs Test titers titration Treatment vaccination Vaccination Status was done were excluded
[DOI] 10.1186/s13045-021-01090-6 PMC 바로가기 [Article Type] Clinical Trial